Skip to main content
PMC home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1995 Jan;71(1):9–12. doi: 10.1038/bjc.1995.3

Analysis of the p53 gene in human choriocarcinoma cell lines.

Y Yaginuma 1, T Yamashita 1, N Takuma 1, H Katayama 1, M Ishikawa 1
PMCID: PMC2033447  PMID: 7819056

Abstract

In the present study, we analysed human choriocarcinoma cell lines for abnormalities in the tumour-suppressor gene p53 by Southern blotting, Northern blotting, non-radioisotopic single-stranded conformational polymorphism (SSCP) and complementary DNA sequencing. In all cell lines (Bewo, GCH-1, GCH-2, SCH, JAR, JEG-3, NUC-1 and HCCM-5), no p53 gene abnormality was detected by using Southern blotting. p53 mRNA of the expected size was detected in all cell lines tested by Northern blotting. SSCP analysis revealed abnormalities of p53 cDNA in the SCH cell line. Sequencing analysis of the entire coding region of the p53 gene revealed that both alleles were expressed in the JEG-3 cell line, and one of the alleles contained a point mutation (G to T) in codon 167 (Gln to His). In the NUC-1 cell line both alleles were point mutated. One allele had a point mutation (A to T) that resulted in a codon 17 change (Glu to Asp), and another had a point mutation (A to T) that caused a codon 24 change (Lys to Asn). In the SCH cell line, AGG was inserted between codon 249 and 250; this insertion resulted in an abnormal structure of the p53 protein. In three out of eight human choriocarcinoma cell lines, a p53 gene abnormality was detected. Therefore our data demonstrate that p53 gene abnormalities are associated with choriocarcinoma cell lines.

Full text

PDF

Images in this article

10Figure 1
on p.10
10Figure 2
on p.10
10Figure 3
on p.10
11Figure 4
on p.11

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Baker S. J., Preisinger A. C., Jessup J. M., Paraskeva C., Markowitz S., Willson J. K., Hamilton S., Vogelstein B. p53 gene mutations occur in combination with 17p allelic deletions as late events in colorectal tumorigenesis. Cancer Res. 1990 Dec 1;50(23):7717–7722. [PubMed] [Google Scholar]
  2. Bishop J. M. Molecular themes in oncogenesis. Cell. 1991 Jan 25;64(2):235–248. doi: 10.1016/0092-8674(91)90636-d. [DOI] [PubMed] [Google Scholar]
  3. Buckley J. D. The epidemiology of molar pregnancy and choriocarcinoma. Clin Obstet Gynecol. 1984 Mar;27(1):153–159. doi: 10.1097/00003081-198403000-00022. [DOI] [PubMed] [Google Scholar]
  4. Davidoff A. M., Kerns B. J., Iglehart J. D., Marks J. R. Maintenance of p53 alterations throughout breast cancer progression. Cancer Res. 1991 May 15;51(10):2605–2610. [PubMed] [Google Scholar]
  5. Hollingsworth R. E., Lee W. H. Tumor suppressor genes: new prospects for cancer research. J Natl Cancer Inst. 1991 Jan 16;83(2):91–96. doi: 10.1093/jnci/83.2.91. [DOI] [PubMed] [Google Scholar]
  6. Imamura J., Bartram C. R., Berthold F., Harms D., Nakamura H., Koeffler H. P. Mutation of the p53 gene in neuroblastoma and its relationship with N-myc amplification. Cancer Res. 1993 Sep 1;53(17):4053–4058. [PubMed] [Google Scholar]
  7. Jones P. A., Buckley J. D. The role of DNA methylation in cancer. Adv Cancer Res. 1990;54:1–23. doi: 10.1016/s0065-230x(08)60806-4. [DOI] [PubMed] [Google Scholar]
  8. Marchetti A., Buttitta F., Merlo G., Diella F., Pellegrini S., Pepe S., Macchiarini P., Chella A., Angeletti C. A., Callahan R. p53 alterations in non-small cell lung cancers correlate with metastatic involvement of hilar and mediastinal lymph nodes. Cancer Res. 1993 Jun 15;53(12):2846–2851. [PubMed] [Google Scholar]
  9. Reiss J., Lenz U., Rininsland F., Ballhausen P., Drews D., Posselt H. G. A novel CFTR mutation, 4035delA, detected by non-radioactive SSCP analysis. Hum Genet. 1992 Nov;90(3):303–304. doi: 10.1007/BF00220085. [DOI] [PubMed] [Google Scholar]
  10. Rideout W. M., 3rd, Coetzee G. A., Olumi A. F., Jones P. A. 5-Methylcytosine as an endogenous mutagen in the human LDL receptor and p53 genes. Science. 1990 Sep 14;249(4974):1288–1290. doi: 10.1126/science.1697983. [DOI] [PubMed] [Google Scholar]
  11. Rodrigues N. R., Rowan A., Smith M. E., Kerr I. B., Bodmer W. F., Gannon J. V., Lane D. P. p53 mutations in colorectal cancer. Proc Natl Acad Sci U S A. 1990 Oct;87(19):7555–7559. doi: 10.1073/pnas.87.19.7555. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Stretch J. R., Gatter K. C., Ralfkiaer E., Lane D. P., Harris A. L. Expression of mutant p53 in melanoma. Cancer Res. 1991 Nov 1;51(21):5976–5979. [PubMed] [Google Scholar]
  13. Yaginuma Y., Fujita M., Saitoh S., Hayakawa K., Kuzumaki N., Ishikawa M. Immunohistochemical analysis of ras oncogene product p21 in human endometrial carcinoma. Acta Histochem. 1993 Sep;95(1):23–29. doi: 10.1016/s0065-1281(11)80383-1. [DOI] [PubMed] [Google Scholar]
  14. Yaginuma Y., Westphal H. Abnormal structure and expression of the p53 gene in human ovarian carcinoma cell lines. Cancer Res. 1992 Aug 1;52(15):4196–4199. [PubMed] [Google Scholar]
  15. Yaginuma Y., Westphal H. Analysis of the p53 gene in human uterine carcinoma cell lines. Cancer Res. 1991 Dec 15;51(24):6506–6509. [PubMed] [Google Scholar]
  16. Zakut-Houri R., Bienz-Tadmor B., Givol D., Oren M. Human p53 cellular tumor antigen: cDNA sequence and expression in COS cells. EMBO J. 1985 May;4(5):1251–1255. doi: 10.1002/j.1460-2075.1985.tb03768.x. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES